Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Pacer Data & Infra Real Estate ETF (SRVR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Pacer Data & Infra Real Estate ETF — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Pacer Data & Infra Real Estate ETF trades at $27.9 (market cap $300.94M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is far larger — about 3.2× Pacer Data & Infra Real Estate ETF's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Pacer Data & Infra Real Estate ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Pacer Data & Infra Real Estate ETF for 16 Days on average.
| MRVI | SRVR | |
|---|---|---|
Market Cap | $972.90M | $300.94M |
Volume | 4,325,710 | 73,849 |
Sector | Health | Sector/Thematic |
52-Week High | $9.00 | $35.74 |
52-Week Low | $2.83 | $27.94 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $1.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
SRVR trades at $28.62, down 1.31% today, with a mixed technical outlook—bullish overall signal but bearish moving averages. Key financial ratios are unavailable, limiting fundamental assessment. Recent news highlights data center ETFs as a way to gain exposure to AI and cloud computing growth, suggesting thematic relevance.
The outlook is cautiously optimistic due to AI-driven demand for data centers, but risks include reliance on thematic trends and lack of current financial data. Investors should seek updated fundamentals to gauge valuation and growth prospects amid competitive and macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Pacer Data & Infra Real Estate ETF
Pacer Data & Infra Real Estate ETF seeks exposure to real estate companies that own digital infrastructure assets. Its holdings may include data centers, cell towers, fiber networks, and other connectivity-related real estate.
Read more on SRVR →
